Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
8 Mar 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
10 Mar 22
Current reports
8-K
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
28 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Mar 24
8-K
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
14 Nov 23
8-K
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
31 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Sep 23
8-K
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
14 Aug 23
8-K
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Other Events
30 May 23
Registration and prospectus
S-8
Registration of securities for employees
11 May 23
424B5
Prospectus supplement for primary offering
15 Feb 23
S-3
Shelf registration
1 Dec 20
S-8
Registration of securities for employees
8 Nov 19
424B4
Prospectus supplement with pricing info
8 Nov 19
8-A12B
Registration of securities on exchange
30 Oct 19
S-1/A
IPO registration (amended)
28 Oct 19
S-1
IPO registration
11 Oct 19
DRS/A
Draft registration statement (amended)
12 Sep 19
DRSLTR
Correspondence regarding draft registration statement
12 Sep 19
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
Other
EFFECT
Notice of effectiveness
10 Dec 20
CORRESP
Correspondence with SEC
7 Dec 20
UPLOAD
Letter from SEC
7 Dec 20
EFFECT
Notice of effectiveness
7 Nov 19
CERT
Certification of approval for exchange listing
6 Nov 19
CORRESP
Correspondence with SEC
4 Nov 19
CORRESP
Correspondence with SEC
4 Nov 19
CORRESP
Correspondence with SEC
18 Oct 19
UPLOAD
Letter from SEC
3 Sep 19
SEC STAFF
SEC staff action: Order
8 May 19
Ownership
SC 13G
ALPHA PHARMA Investments LLC
16 Apr 24
SC 13G/A
Altamont Pharmaceutical Holdings, LLC
3 Apr 24
5
Mark E. Pearson
1 Apr 24
4
Yair Schneid
26 Feb 24
SC 13D/A
Sofinnova Venture Partners IX, L.P.
20 Feb 24
SC 13G/A
SECTORAL ASSET MANAGEMENT INC
14 Feb 24
SC 13G
Schneid Yair
17 Jan 24
3
Yair Schneid
16 Jan 24
SC 13G
GSA CAPITAL PARTNERS LLP
2 Jan 24
SC 13D/A
Blackstone Holdings I/II GP L.L.C.
4 Dec 23